Adma Biologics vs Arcutis Biotherapeutics
Adma Biologics is the larger business, with $510m of revenue in fiscal 2025 against $376m for Arcutis Biotherapeutics (1.4 times as much). Arcutis Biotherapeutics grew faster (91.3% against 19.6%). Adma Biologics kept more of each dollar of sales as profit: a net margin of 28.8% against -4.3%.
| Latest fiscal year | Adma BiologicsADMA, 2025 | Arcutis BiotherapeuticsARQT, 2025 |
|---|---|---|
| Revenue | $510m | $376m |
| Revenue growth | 19.6% | 91.3% |
| Net income | $147m | −$16.1m |
| Operating margin | — | -3.3% |
| Net margin | 28.8% | -4.3% |
| Return on equity | 35.6% | -9.3% |
| Free cash flow | $27.8m | −$6.3m |
| Cash | $87.6m | $42.9m |
| Total debt | $72.1m | $109m |
| Debt to equity | — | 57.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $31.9m | — |
| Employees | 647 | 354 |
| Market value | $2.48bn | $4.02bn |
| Price vs our value range | Within our value range | — |
| Moat score | 40 (Weak) | — |
| Insider trades, 12 months | 5 buys, 9 sales | 0 buys, 77 sales |